Introduction
============

The ataxia telangiectasia (A-T) mutated (ATM) kinase plays a key role in the DNA damage response by phosphorylating numerous substrates that signal for DNA repair, cell cycle checkpoint activation, and apoptosis ([@bib3]; [@bib17]; [@bib45]; [@bib7]; [@bib52]; [@bib6]). The critical function of ATM is underscored by its high conservation in eukaryotes and its deficiency in the recessive, cancer-prone A-T disease ([@bib60]). The exact mechanism by which ATM is activated in vivo still remains unclear ([@bib55]; [@bib20]), but one current model suggests that autophosphorylation triggers its activation ([@bib2]; [@bib37], [@bib38]; [@bib63]). A prediction is that loss of ATM kinase activity would be equivalent to loss of the ATM protein. Indeed, patient cells reconstituted with kinase-inactive ATM ([@bib2]) and treatment of cells with a pharmacological ATM kinase inhibitor ([@bib32]; [@bib9]; [@bib15]; [@bib57]; [@bib70]) support the notion that inhibition of cellular ATM kinase activity mirrors complete ATM deficiency.

The classical form of A-T is most frequently caused by compound heterozygote-truncating mutations that result in a total loss of destabilized ATM protein (∼90% of cases; [@bib29]; [@bib39]; [@bib42]; [@bib48]). Mouse models deficient in ATM have been invaluable for the study of A-T ([@bib4]; [@bib27]; [@bib73]; [@bib23]; [@bib40]; [@bib66]). In stark contrast to *Atm*-null mice ([@bib4]; [@bib27]; [@bib73]), we show here that single point mutations disrupting the kinase activity of ATM lead to early embryonic lethality in mice. These results reveal a previously unknown essential role for ATM kinase activity during embryonic development and provide a potential explanation for why kinase-inactive missense mutations do not constitute a significant portion of the molecular lesions in childhood A-T. Furthermore, our finding that inhibition of ATM kinase activity in vivo does not always equate to complete loss of ATM protein suggests that treatments using ATM inhibitors (ATMi's) could be more toxic than previously anticipated.

Results and discussion
======================

Mutations in the ATM kinase domain display severely impaired kinase activity in vitro and cause embryonic lethality in mice
---------------------------------------------------------------------------------------------------------------------------

To determine whether the diverse in vivo functions of ATM are mediated solely by its kinase domain, we used bacterial artificial chromosome (BAC) recombineering to generate two kinase-inactive mouse models of ATM. To identify a single residue for mutagenesis without any high-resolution structural information for ATM, we took two approaches. In a structural modeling approach, we identified the p110 phosphoinositide 3-kinase domain as having a statistically significant protein sequence alignment with the ATM kinase domain and found that an essential catalytic aspartic acid residue in the active site of the p110 kinase structure aligns with D2889 of human ATM. Moreover, a p110 knockin mouse substituting this residue with alanine, *p110δ*^D910A/D910A^, demonstrated that this mutation abolishes kinase activity in vitro and in vivo without affecting protein stability ([@bib51]); therefore, we chose to generate the conserved D2899A mutation in the mouse ([Fig. 1 A](#fig1){ref-type="fig"}). For the second approach, we decided to model a rare missense variant from a patient with classical A-T, c.8189A\>C (p.Gln2730Pro), whose cells displayed ATM protein expression without detectable kinase activity ([@bib67]; [@bib5]).

![**ATM D2899A and Q2740P mutations display severely impaired kinase activity in vitro and cause embryonic lethality in mice.** (A) Pairwise local alignments of human (*Homo sapiens*) and mouse (*Mus musculus*) ATM protein sequences surrounding sites of mutagenesis. (B) Kinase assay with 0.2 nM WT, D2889A, or Q2730P mutant dimeric human ATM, 3.6 nM MRN, 50 nM GST-p53 substrate, and linear DNA probed with an antibody to p53 S15 phosphorylation. A titration of ATM is shown for each sample. (C) Sequence chromatograms showing the amino acid mutations generated in mouse BAC RP24-122F10. (D and E) Thymocytes were harvested for lysate preparation and Western blot analysis. Molecular mass markers are in kilodaltons. (F and G) Tables showing the expected and observed genotypes of 3-wk-old pups from breeding *Atm*^Tg^*Atm*^+/−^ with *Atm*^+/−^ mice. The boxes highlight the comparison between the total number of ATM kinase-inactive and *Atm*-null live-born pups.](JCB_201204035_Fig1){#fig1}

Before generating BAC transgenic mouse models, we tested whether the D2889A and Q2730P mutations in human ATM are required for ATM kinase activity in a completely reconstituted system. Kinase assays with wild-type (WT), D2889A, and Q2730P mutant dimeric human ATM complexes were performed using p53 as a substrate ([@bib41]). Although WT ATM dimers displayed p53 S15 phosphorylation in an MRN (MRE11-RAD50-NBS1)- and DNA-dependent manner, kinase activity of D2889A and Q2730P mutant dimers was completely abolished ([Fig. 1 B](#fig1){ref-type="fig"}). Thus, the D2889A and Q2730P mutations are required for human ATM kinase activity.

As both D2889 and Q2730 residues in human ATM are conserved in the mouse ([Fig. 1 A](#fig1){ref-type="fig"}), we recombineered the equivalent mutations in a WT BAC spanning the genomic mouse *Atm* locus to generate BAC transgenic mice as previously described ([@bib55]; [@bib20]). Both mutation sites were confirmed by sequencing ([Fig. 1 C](#fig1){ref-type="fig"}). Founder lines expressing mutant murine ATM from the BAC transgene were identified and bred to *Atm*^+/−^. Founder lines G1 and H7 of *Atm*^TgD2899A^ mice expressed transgenic murine ATM near the level observed in *Atm*^+/−^ mice, whereas founder lines F5, D4, and I2 overexpressed murine ATM ([Fig. 1 D](#fig1){ref-type="fig"}). For *Atm*^TgQ2740P^ mice, founder line G4 expressed transgenic murine ATM near the level observed in *Atm*^+/+^ mice, whereas the C8 and A3 founder lines overexpressed ATM ([Fig. 1 E](#fig1){ref-type="fig"}). Similar ATM protein levels were observed from splenocytes and thymocytes of transgenic animals ([Fig. 1, D and E](#fig1){ref-type="fig"}; and not depicted).

We crossed *Atm*^TgD2899A^*Atm*^+/−^ and *Atm*^TgQ2740P^*Atm*^+/−^ mice with *Atm*^+/−^ but, to our surprise, failed to generate transgenic animals on the *Atm*^−/−^ background ([Fig. 1, F and G](#fig1){ref-type="fig"}). This failure to generate *Atm*^Tg^*Atm*^−/−^ live-born pups was observed across all founder lines of both mutations ([Fig. 1, F and G](#fig1){ref-type="fig"}) and was not the result of transgene integration on the chromosome containing endogenous *Atm*, as shown by FISH ([Fig. S1](http://www.jcb.org/cgi/content/full/jcb.201204035/DC1){#supp1}). To begin to elucidate the stage of embryonic development that is impaired with deficient ATM kinase activity, we prepared embryos at embryonic day 9.5 (E9.5) from D2899A mutant mice. We found that *Atm*^TgD2899A^*Atm*^−/−^ embryos were produced at a dramatically lower frequency than expected, indicating that D2899A mutant embryos die before E9.5 ([Table 1](#tbl1){ref-type="table"}). Transgenic animals with one or both WT copies of *Atm* were found at the expected frequency, indicating an absence of dominant-negative interfering activity. We conclude that the kinase-inactive ATM mutation leads to early embryonic lethality in mice.

###### 

Embryonic lethality of ATM D2899A mice occurs before E9.5

  Founder line                  Atm^TgD2899A^Atm^+/+^   Atm^+/+^   Atm^TgD2899A^Atm^+/−^   Atm^+/−^   Atm^TgD2899A^Atm^−/−^   Atm^−/−^   Total genotyped   Absorb
  ----------------------------- ----------------------- ---------- ----------------------- ---------- ----------------------- ---------- ----------------- --------
  G1 observed                   3                       9          7                       13         1                       5          38                5
  G1 expected                   5                       5          10                      10         5                       5                            
  H7 observed                   0                       5          2                       8          0                       2          17                2
  H7 expected                   2                       2          4                       4          2                       2                            
  D4 observed                   0                       4          0                       1          0                       0          5                 1
  D4 expected                   0.5                     0.5        1                       1          0.5                     0.5                          
  F5 observed                   1                       4          5                       2          0                       0          12                3
  F5 expected                   1.5                     1.5        3                       3          1.5                     1.5                          
  I2 observed                   4                       3          4                       6          0                       2          19                4
  I2 expected                   2                       2          5                       5          2                       2                            
  Total E9.5 embryos observed   11                      25         18                      30         1                       9          91                15
  Total E9.5 embryos expected   11                      11         23                      23         11                      11                           

Shown are the expected and observed genotypes from breeding *Atm*^TgD2899A^*Atm*^+/−^ with *Atm*^+/−^ mice. Note the comparison between the total number of ATM kinase-inactive and *Atm*-null embryos.

We speculated that the severe defect during embryogenesis is the result of ATM kinase recruitment at DNA breaks, which may impair the function of other proteins by occluding their access to DNA damage. To support this, we found that a kinase-inactive human ATM D2870A mutant protein, expressed in cells that do not express endogenous ATM, is recruited to sites of laser-induced DNA damage ([Fig. S2](http://www.jcb.org/cgi/content/full/jcb.201204035/DC1){#supp2}). Moreover, WT human ATM was similarly recruited to DNA damage sites in cells treated with the KU55933 ATMi (Fig. S2). These results are consistent with other studies in human cells showing that ATM kinase activity is dispensable for recruitment of epitope-tagged ATM to sites of DNA breaks after laser- or ionizing radiation (IR)--induced DNA damage ([@bib5]; [@bib21]). They are also consistent with results from *Xenopus laevis* egg extracts showing an increase in ATM association to damaged chromatin in the presence of caffeine or the KU55933 ATMi ([@bib75], [@bib76]).

Double-stranded break (DSB)--induced activation and recruitment of ATM to chromatin is dependent on *Nbs1* ([@bib68]; [@bib24]). If recruitment of kinase-dead ATM to DNA breaks is toxic, we reasoned that we might be able to rescue viability by breeding with *Nbs1*^ΔB/ΔB^ mice, a hypomorphic *Nbs1* mutant mouse that exhibits a mild defect in ATM activation ([@bib71]). However, no *Nbs1*^ΔB/ΔB^*Atm*^TgD2899A^*Atm*^−/−^ mice were born ([Table 2](#tbl2){ref-type="table"}). Thus, a mutation that is predicted to reduce ATM activation and association with chromatin cannot rescue viability of ATM kinase-inactive mice.

###### 

Embryonic lethality of ATM D2899A (G1 founder line) mice is not rescued by disruption of *Nbs1*, *Ku80*, or *53bp1*

  Genotype               Atm^TgD2899A^Atm^+/+^   Atm^+/+^   Atm^TgD2899A^Atm^+/−^   Atm^+/−^   Atm^TgD2899A^Atm^−/−^   Atm^−/−^
  ---------------------- ----------------------- ---------- ----------------------- ---------- ----------------------- ----------
  Nbs1^+/+^ observed     9                       10         14                      10         0                       11
  Nbs1^+/+^ expected     7                       7          15                      15         7                       7
  Nbs1^ΔB/+^ observed    16                      20         42                      38         0                       16
  Nbs1^ΔB/+^ expected    15                      15         30                      30         15                      15
  Nbs1^ΔB/ΔB^ observed   7                       12         14                      19         0                       0
  Nbs1^ΔB/ΔB^ expected   7                       7          15                      15         7                       7
  Ku80^+/+^ observed     16                      9          21                      16         0                       2
  Ku80^+/+^ expected     10                      3          19                      6          10                      3
  Ku80^+/−^ observed     21                      16         41                      26         0                       9
  Ku80^+/−^ expected     19                      6          39                      13         19                      6
  Ku80^−/−^ observed     9                       1          17                      3          0                       0
  Ku80^−/−^ expected     10                      3          19                      6          10                      3
  53bp1^−/−^ observed    14                      11         52                      19         0                       6
  53bp1^−/−^ expected    19                      6          38                      13         19                      6

Shown are the expected and observed genotypes of 3-wk-old pups from breeding *Nbs1*^ΔB/+^*Atm*^TgD2899A^*Atm*^+/−^ with *Nbs1*^ΔB/+^*Atm*^+/−^ mice (*n* = 238), intercrossing *Ku80*^+/−^*Atm*^TgD2899A^*Atm*^+/−^ mice (*n* = 207), or intercrossing *53bp1*^−/−^*Atm*^TgD2899A^*Atm*^+/−^ mice (*n* = 102). Note the numbers of ATM kinase-inactive live-born pups in the different *Ku80* backgrounds, the comparison between the number of ATM kinase-inactive and *Atm*-null live-born pups in the 53bp1^-/-^ background, and the numbers of ATM kinase-inactive live-born pups in the different Nbs1 backgrounds.

Recently, a DNA-dependent protein kinase, catalytic subunit (DNA-PKcs) mutant mouse model with three phosphorylation site substitutions revealed that the DNA-PKcs mutant protein causes a more severe phenotype than *Dnapkcs*-null mice ([@bib78]). Because DNA-PKcs has overlapping functions with ATM ([@bib31]; [@bib61]; [@bib16]; [@bib28]), we reasoned that if ATM and DNA-PKcs are being recruited to DNA breaks and occluding access of other factors, disruption of the DNA-dependent protein kinase holoenzyme may partially alleviate the toxic effect of kinase-inactive ATM. To test this hypothesis, we crossed *Ku80*-null mice ([@bib50]) with our kinase-inactive ATM mice. However, *Atm*^TgD2899A^*Atm*^−/−^ live-born pups were not recovered in the *Ku80*^−/−^ background ([Table 2](#tbl2){ref-type="table"}), suggesting that disruption of DNA-PKcs recruitment to DNA breaks does not rescue ATM kinase-inactive toxicity. Similarly, loss of 53BP1, which reduces nonhomologous end joining (NHEJ) and promotes resection of DSBs ([@bib69]; [@bib72]; [@bib25]; [@bib26]; [@bib13]), also did not rescue the viability of *Atm*^TgD2899A^*Atm*^−/−^ mice ([Table 2](#tbl2){ref-type="table"}).

Conditional ATM D2899A B lymphocytes display defects in development, genome stability, and sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitor
-------------------------------------------------------------------------------------------------------------------------------------------------------

To overcome the embryonic lethality of *Atm*^TgD2899A^*Atm*^−/−^ mice, we crossed a previously described conditional *Atm* knockout allele ([@bib77]) and CD19-cre ([@bib59]) to our *Atm* transgenic mice for generating ATM kinase-inactive primary B cells. With this model, we investigated the effect of ATM kinase inhibition on DNA damage signaling, lymphocyte development, and genome stability. To monitor the frequency of Cre recombinase--expressing cells in these mice, we crossed in the Rosa26-stop-YFP allele ([@bib64]) to generate *Cd19*^cre/+^*Rosa26*^YFP/+^*Atm*^TgD2899A^*Atm*^flox/−^ mice (herein referred to as *Atm*^TgD2899A^*Atm*^flox/−^) and compared with littermate ATM-deficient control mice (*Cd19*^cre/+^*Rosa26*^YFP/+^*Atm*^flox/−^, herein referred to as *Atm*^flox/−^). To verify deletion efficiency, we sorted live YFP^+^ cells from *Atm*^TgD2899A^*Atm*^flox/−^ and control splenic B cell cultures and demonstrated that, although *Atm*^flox/−^ cells have no detectable ATM protein as measured by Western blotting, *Atm*^TgD2899A^*Atm*^flox/−^ cells displayed levels similar to *Atm*^flox/+^ cells ([Fig. 2 A](#fig2){ref-type="fig"}). To test whether the D2899A mutation abrogates ATM kinase activity in vivo, splenic B cells were irradiated with 10 Gy, and KAP1 S824 phosphorylation was assessed by Western blotting. Although *Atm*^flox/+^ cells responded normally to γ irradiation with robust KAP1 S824 phosphorylation, *Atm*^TgD2899A^*Atm*^flox/−^ and *Atm*^flox/−^ B cells behaved similarly, displaying severely impaired phosphorylation ([Fig. 2 A](#fig2){ref-type="fig"}). We conclude that ATM D2899A mutant murine B cells are deficient in IR-induced ATM kinase activity in vivo similar to ATM-deficient cells.

![**Conditional ATM D2899A mice display defects mildly more severe than ATM deficiency in B cell development, genome stability, and sensitivity to PARP inhibitor.** (A) Western blot analysis of splenic B cells stimulated with LPS and RP105 for 72 h, FACS sorted for YFP expression, and harvested for lysate preparation after a 10-Gy irradiation. Shown for comparison are sorted cells from two individual *Atm*^TgD2899A^*Atm*^flox/−^ mice. In addition to the labeled *Atm* genotype, note that mice are also *Cd19*^cre/+^*Rosa26*^YFP/+^, for which YFP expression (as a marker of Cre recombinase expression) is found in pro-B cells and becomes progressively higher through B cell development to the mature B cell stage. Molecular mass markers are in kilodaltons. (B) YFP^+^ frequency from freshly isolated B cells of the following subsets of bone marrow and spleen harvested and stained with antibodies to B220, CD43, and IgM for flow cytometric analysis. Pro-B (B220^+^CD43^+^IgM^−^), pre-B (B220^+^CD43^−^IgM^−^), immature B (B220^+^CD43^−^IgM^int^), mature B (B220^+^IgM^+^), and splenic mature B (B220^+^IgM^+^) are shown. \*, P \< 0.00001. (C) YFP^+^ absolute cell numbers from each subset in bone marrow and spleen. Legend same as in B. \*, P \< 0.05. (D) YFP^+^ fraction of live B220^+^ splenic B cells stimulated with LPS as a function of days in culture. Each data point represents the YFP^+^ frequency measured by flow cytometry, relative to day 0. For days 5 and 6, P \< 0.0001 for *Atm*^TgD2899A^*Atm*^flox/−^ versus *Atm*^flox/+^, and P \< 0.05 for *Atm*^TgD2899A^*Atm*^flox/−^ versus *Atm*^flox/−^. (E) Splenic YFP^+^ B cells stimulated with LPS, IL4, and RP105 for 72 h were harvested for metaphase chromosome preparation. FISH was performed on slides with a probe for telomeres and counterstained with DAPI. Frequency of aberrations per metaphase is shown for chromatid breaks (CTB), chromosome breaks (CSB), radials, and translocations (*Atm*^flox/+^: *n* = 105 from 1 mouse; *Atm*^TgD2899A^*Atm*^flox/−^: *n* = 313 from 3 mice; *Atm*^flox/−^: *n* = 200 from 2 mice). (F) YFP^+^ fraction of live B220^+^ splenic B cells stimulated with LPS and 1 µM PARP inhibitor. Each data point represents the YFP^+^ frequency measured by flow cytometry relative to no treatment of the same genotype. Legend same as in D. On days 3 and 4, P \< 0.05 for *Atm*^TgD2899A^*Atm*^flox/−^ versus *Atm*^flox/−^. Error bars represent standard deviation. PARPi, PARP inhibitor.](JCB_201204035_Fig2){#fig2}

To assess the role of ATM kinase activity during B cell development, we performed flow cytometric analyses on freshly isolated bone marrow and splenocytes. *Atm*^TgD2899A^*Atm*^flox/−^ mice displayed significant decreases in the frequency and number of YFP^+^ cells in developing and mature B cell subsets in bone marrow and spleen compared with the similar frequencies observed between *Atm*^flox/−^ and *Atm*^flox/+^ mice ([Fig. 2, B and C](#fig2){ref-type="fig"}; and [Fig. S3](http://www.jcb.org/cgi/content/full/jcb.201204035/DC1){#supp3}). Thus, different from ATM-deficient cells, Cre-expressing YFP^+^ cells with the D2899A mutant form of ATM as their sole ATM species are out competed in vivo by cells that express a WT copy of *Atm*. To test whether the D2899A mutation causes defects in the overall fitness of stimulated cells, we activated splenic B cells in culture with lipopolysaccharide (LPS) and IL4 and monitored YFP frequency of B220^+^ cells over time by flow cytometry. Although YFP frequency in live *Atm*^flox/+^ B cells remained constant over 6 d in culture, *Atm*^TgD2899A^*Atm*^flox/−^ B cells displayed a reproducible decrease in YFP frequency, with *Atm*^flox/−^ B cells showing an intermediate phenotype ([Fig. 2 D](#fig2){ref-type="fig"}). *Atm*^TgD2899A^*Atm*^flox/+^ B cells expressing WT ATM showed similar results as *Atm*^flox/+^ B cells ([Fig. 2 D](#fig2){ref-type="fig"}), supporting an absence of dominant-negative interfering activity in the D2899A mutant. Thus, although the D2899A point mutation in mice leads to severe defects in embryonic development, defects in B lymphocyte development and activation are only mildly more severe than ATM-deficient controls.

Chromosomal instability is a hallmark of both human and murine ATM-deficient cells ([@bib73]; [@bib62]; [@bib15]) and is also a rapid consequence of treatment of WT cells with ATM kinase inhibitors ([@bib32]; [@bib9]; [@bib15]; [@bib57]; [@bib70]). To test whether genetic ablation of the murine ATM kinase causes defects in genome stability, metaphase chromosome spreads of YFP^+^ cells sorted from *Atm*^TgD2899A^*Atm*^flox/−^ and control B cell cultures were analyzed for chromosome abnormalities. As expected, ATM-deficient cells displayed a higher number of aberrations per cell compared with controls ([Fig. 2 E](#fig2){ref-type="fig"}). *Atm*^TgD2899A^*Atm*^flox/−^ cells showed a 1.7-fold increase in aberrations per cell compared with ATM-deficient cells, marked by chromosome breaks and chromatid breaks ([Fig. 2 E](#fig2){ref-type="fig"}). We conclude that ATM D2899A mutant murine B cells exhibit more genomic instability than ATM-deficient control cells.

The increase in chromatid breaks observed in D2899A mutant cells suggested that these cells may have more severely impaired homologous recombination (HR). To test this, we used flow cytometry to assess the YFP frequency of live B220^+^ cells cultured with PARP inhibitor. Relative to the YFP frequency measured with no drug treatment, this assay recapitulated the reported sensitivity of ATM-deficient human cells to PARP inhibitor ([Fig. 2 F](#fig2){ref-type="fig"}; [@bib11]; [@bib46]). Using YFP as a marker for Cre-expressing cells in competition with nondeleted cells, our analyses indicated that *Atm*^TgD2899A^*Atm*^flox/−^ cells were mildly more sensitive to PARP inhibitor treatment compared with ATM-deficient cells ([Fig. 2 F](#fig2){ref-type="fig"}), suggesting a more significant defect in HR. We conclude that D2899A mutant murine B cells display more severe defects in genome stability and PARP inhibitor sensitivity compared with ATM-deficient cells.

Conditional ATM D2899A B lymphocytes display defects in variable, diversity, and joining (V(D)J) recombination and immunoglobulin class switching
-------------------------------------------------------------------------------------------------------------------------------------------------

Deficiency in murine ATM leads to impaired DNA end joining in lymphocytes undergoing V(D)J recombination ([@bib9]). To test whether the D2899A mutation causes similar V(D)J recombination defects, we generated v-Abl (viral Abl) kinase-transformed pre-B cell lines (herein referred to as abl pre-B cells) from bone marrow of *Atm*^TgD2899A^*Atm*^flox/−^ mice expressing an *Eμ-Bcl2* transgene. These cells were transiently transfected with Cre recombinase to generate *Atm*^TgD2899A^*Atm*^Δ/−^ abl pre-B cells and retrovirally infected with the pMX-INV recombination substrate to generate *Atm*^TgD2899A^*Atm*^Δ/−^:*INV* abl pre-B cells. To induce recombination activating gene (RAG)--mediated DSBs, *Atm*^+/+^:*INV*, *Atm*^TgD2899A^*Atm*^Δ/−^:*INV*, and *Atm*^−/−^:*INV* abl pre-B cells were treated with the Abl kinase inhibitor STI571. Southern blot analysis of pMX-INV rearrangement revealed that the defects in V(D)J recombination in *Atm*^TgD2899A^*Atm*^Δ/−^:*INV* abl pre-B cells were similar to those observed in *Atm*^−/−^:*INV* abl pre-B cells. Specifically, there was a decrease in normal coding joint formation with an accumulation of unrepaired coding ends and an increase in hybrid joint formation (Fig. S3). We conclude that ATM D2899A mutant murine lymphocytes display V(D)J recombination defects similar to *Atm*-null lymphocytes.

During an immune response, physiological DSBs at the IgH locus occur in B lymphocytes during class switch recombination (CSR; [@bib65]). ATM is required for efficient CSR and has been proposed to play a role as a DNA damage response factor in the synapsis of two broken switch regions ([@bib54]; [@bib44]; [@bib58]). To test whether the D2899A mutation affects CSR, splenic B cells from *Atm*^TgD2899A^*Atm*^flox/−^ and control mice were stimulated with LPS and IL4, and the frequency of YFP^+^ cells positive for surface IgG1 was assessed by flow cytometry. Consistent with previous studies using germline *Atm*^−/−^ mice ([@bib44]; [@bib58]), B cells from *Atm*^flox/−^ mice with CD19-cre led to a 2.5-fold decrease in IgG1 CSR, relative to the IgG1^+^ frequency in YFP^+^ cells from *Atm*^flox/+^ mice ([Fig. 3, A and B](#fig3){ref-type="fig"}). B cells from *Atm*^TgD2899A^*Atm*^flox/−^ mice displayed a 1.9-fold defect in IgG1 CSR, albeit less severe than ATM-deficient controls ([Fig. 3, A and B](#fig3){ref-type="fig"}). We conclude that ATM D2899A mutant B cells display defects in CSR that are mildly less severe than ATM-deficient controls.

![**Conditional ATM D2899A B cells display defects in immunoglobulin class switching without impairing DNA-PKcs or ATR.** (A) Flow cytometric analysis of IgG1 expression on B cells stimulated with LPS and IL4 for 5 d. (B) Mean percentage of IgG1 class switching from multiple flow cytometric analyses as in B (\*, P \< 0.05). (C) Mean percentage of IgG1 class switching of YFP^+^ splenic B cells treated with DNA-PKcs inhibitor NU7026 (PKi) or DMSO (\*, P \< 0.05). (D) Splenic B cells stimulated with LPS and RP105 for 72 h were treated with 2 mM hydroxyurea (HU) for 2 h, FACS sorted for YFP expression, and harvested for lysate preparation and Western blot analysis. Shown for comparison are sorted cells from two individual *Atm*^TgD2899A^*Atm*^flox/−^ mice along with *Atm*^+/+^ and *Atm*^−/−^ unsorted B cells. Molecular mass markers are in kilodaltons. Error bars represent standard deviation.](JCB_201204035_Fig3){#fig3}

DNA-PKcs and A-T and Rad3 related (ATR) are functional in conditional ATM D2899A B cells
----------------------------------------------------------------------------------------

Because DNA-PKcs and ATM have redundant roles in development and CSR ([@bib31]; [@bib61]; [@bib16]), we directly tested whether DNA-PKcs kinase activity is functional during CSR in D2899A mutant B cells. To this end, we stimulated *Atm*^TgD2899A^*Atm*^flox/−^ and control cells to undergo CSR in the presence or absence of the DNA-PKcs inhibitor NU7026 ([@bib16]). In contrast to *Atm*^flox/+^ cells, inhibiting DNA-PKcs kinase activity in either *Atm*^TgD2899A^*Atm*^flox/−^ or *Atm*^flox/−^ B cells resulted in a nearly twofold reduction in IgG1 CSR ([Fig. 3 C](#fig3){ref-type="fig"}), a decrease consistent with PKcs inhibitor treatment of germline *Atm*^−/−^ B cells ([@bib16]). We conclude that DNA-PKcs is functional in conditional ATM D2899A mutant B cells.

A different phosphoinositide 3-kinase--like kinase, ATR, is required for cell cycle progression and genome stability during replicative stress ([@bib10]; [@bib43]), and there is evidence that ATM can regulate ATR function. For example, ATM is required for ATR activation and CHK1 phosphorylation in response to IR; however, ATR-dependent CHK1 phosphorylation in response to replication-associated DNA damage occurs independently of ATM ([@bib1]; [@bib19]; [@bib35]; [@bib49]). To test whether ATR is functional in ATM D2899A mutant cells, we examined CHK1 S317 phosphorylation in YFP^+^ sorted *Atm*^TgD2899A^*Atm*^flox/−^ and control cultured B cells treated with hydroxyurea. We found that hydroxyurea-induced CHK1 S317 phosphorylation was indistinguishable between mutant and control cells ([Fig. 3 D](#fig3){ref-type="fig"}). Double deficiency in the human ATM and ATR kinases leads to extensive chromosome fragmentation in the presence of the DNA replication inhibitor aphidicolin ([@bib53]); however, *Atm*^TgD2899A^*Atm*^flox/−^ cells were also indistinguishable from controls in response to aphidicolin in our previously described flow cytometric YFP frequency assay (unpublished data). Altogether, our results indicate that expression of kinase-inactive murine ATM does not abrogate DNA-PKcs or ATR function in B cells.

Although an explanation for the embryonic lethality in kinase-inactive ATM mice is yet to be determined, *Atm*-null mutations clearly can become embryonically lethal when combined with deficiencies in various DNA damage response pathways. For instance, *Atm*-null mice show embryonic lethality when disrupted in combination with *Fancg*^−/−^ ([@bib36]), *Parp1*^−/−^ (E8.0; [@bib47]), *Parp2*^−/−^ (between E9.5 and newborn; [@bib33]), *Ku70*^−/−^ and *Ku80*^−/−^ (earlier than E11.5), *Dnapkcs*^−/−^ (E7.5--8.5; [@bib31]; [@bib61]; [@bib30]), *H2ax*^−/−^ (E11.5--12.5; [@bib77]), and *Nbs1*^ΔB/ΔB^ (E10; [@bib71]). Some of these synthetic lethal interactions may arise from additive defects in DNA repair. For example, it is possible that *Nbs1*^ΔB/ΔB^ mice are synthetically lethal with *Atm*^−/−^ ([@bib71]) because of the essential role of the MRN complex in DSB resection that is independent of its function in murine ATM activation ([@bib12]). In dividing embryonic cells, an HR defect in *Nbs1*^ΔB/ΔB^ mice may synergize with ATM deficiency to cause an accumulation of DNA damage above a tolerable threshold. Similarly, we found that D2899A mutant B cells were mildly more sensitive than ATM-deficient controls to PARP inhibition, and we hypothesize that this may be caused by a more severe decrease in resection. Although D2899A mutant B cells show a decrease in HR, they also show a mild increase in the frequency of class switching compared with ATM-deficient cells, suggestive of increased NHEJ activity. Based on these findings, we suggest that the mild imbalances in DNA repair pathways in *Atm*^TgD2899A^*Atm*^−/−^ cells above those governed by ATM could result in very severe developmental defects, while having less dramatic outcomes in adult tissues.

Only rarely do A-T patients with the classical phenotype display relatively normal ATM protein levels without detectable kinase activity ([@bib5]; [@bib22]; [@bib34]). We hypothesize that similar kinase-inactive mutations also cause embryonic lethality in humans and expect that patients with a similar genotype as the one modeled here must have additional mutations to bypass the embryogenesis defect. Indeed, there is clear precedence for secondary mutations that rebalance DSB repair pathways and alleviate early embryonically lethal phenotypes. For example, loss of the NHEJ factor 53BP1 rescues the early embryonic lethality observed in *Brca1*-null mice ([@bib18]; [@bib8]; [@bib14]). Although loss of 53BP1 and Ku deficiency both increase HR ([@bib56]; [@bib13], [@bib14]), *53bp1*^−/−^*Atm*^TgD2899A^*Atm*^−/−^ mice and *Ku80*^−/−^*Atm*^TgD2899A^*Atm*^−/−^ mice were not obtained ([Table 2](#tbl2){ref-type="table"}), suggesting that other mutations might compensate for kinase-inactive ATM protein. In sum, our results contribute a novel perspective to the role of ATM kinase activity during embryogenesis and raise caution regarding the consequences of ATMi treatment in cancer patients and in experimental systems.

Materials and methods
=====================

Generation of mice
------------------

The D2899A and Q2740P mutations were targeted using BAC recombineering as previously described ([@bib74]; [@bib55]; [@bib20]). In brief, mutations were introduced into the murine *Atm* BAC RP24-122F10, which consists of a 160-kb insert including 48.3 kb of sequence upstream and 17.9 kb of sequence downstream of the *Atm* initiation and stop codons, respectively, along with an engineered EcoRI site between exons 35 and 36 for a PCR-based method to distinguish between *Atm*^Tg^*Atm*^−/−^ and *Atm*^Tg^*Atm*^+/−^ genotypes as described previously ([@bib55]; [@bib20]). Both mutant BACs were used to generate transgenic mice. The presence of the transgene was determined by PCR as previously described ([@bib55]) using mouse ATM forward, 5′-AGCACAACCACACTGAATGC-3′, and SP6R, 5′-GTTTTTTGCGATCTGCCGTTTC-3′, primers. To distinguish between *Atm*^Tg^*Atm*^−/−^ and *Atm*^Tg^*Atm*^+/−^ genotypes, EcoRI digestion of the PCR-purified product from amplification using mouse ATM 5B, 5′-GCAGATCCTAAGTAGGTGAGCT-3′, and ATM WT reverse, 5′-CGAATTTGCAGGAGTTGCTGAG-3′, primers was performed. *Atm*^Tg^*Atm*^+/−^ mice yielded the predicted digest products running at 600, 400, and 200 bp, whereas *Atm*^Tg^*Atm*^−/−^ mice yielded the predicted products at 400 and 200 bp. Transgenic founders were crossed to *Atm*^+/−^ mice. All experiments were performed in compliance with the Animal Welfare Act regulations and other federal statutes relating to animals and adhered to the principles set forth in the Guide for Care and Use of Laboratory Animals (National Research Council, 1996). J. Petrini (Memorial Sloan-Kettering Cancer Center, New York, NY) provided *Nbs1*^ΔB^ mice. F. Alt (Harvard Medical School, Boston, MA) provided *Atm* conditional knockout mice.

Lymphocyte cultures, flow cytometry, and genome stability
---------------------------------------------------------

Single-cell suspensions of ACK-treated bone marrow and splenocytes from 6--12-wk-old mice were stained with α-B220--FITC, α-IgM--R-phycoerythrin, and α-CD43--biotin followed by streptavidin-allophycocyanin. Cultured B cells were isolated from spleens of 6--12-wk-old mice by immunomagnetic depletion with anti-CD43 beads (Miltenyi Biotec) and stimulated with either 25 mg/ml LPS (Sigma-Aldrich), 5 ng/ml interleukin 4 (Sigma-Aldrich), and/or 2.5 µg/ml RP105 (BD) as indicated. For assaying class switching, cultured B cells were harvested and stained in single-cell suspensions with α-IgG1--biotin followed by streptavidin--R-phycoerythrin. Cells were acquired through a propidium iodide--negative live-lymphocyte gate with either a FACSCalibur (BD) or an LSR II (BD) flow cytometer. Live YFP^+^ cells were sorted on a cell sorter (FACSAria II; BD). Data were analyzed using FlowJo software (Tree Star). All statistical significance analyses were determined by a two-tailed *t* test assuming unequal variance. For genome stability analyses, cultured B cells were arrested at mitosis with 0.1 µg/ml colcemid (Roche) treatment for 1 h, live YFP^+^ cells were sorted by FACS, and metaphase chromosome spreads were prepared following standard procedures. FISH was performed on slides with a probe for telomere repeat--specific peptide nucleic acid conjugated to Cy3 fluorochrome (Panagene) and counterstained with DAPI. Metaphase images were acquired with an upright microscope (Axioplan 2; Carl Zeiss) equipped with a 63×, NA 1.4 objective lens (Plan-Apochromat; Nikon) and a monochrome charge-coupled device camera (ORCA-ER; Hamamatsu Photonics) using MetaMorph software (Molecular Devices). Abl cell lines were generated, and V(D)J recombination was assayed as described including the *Atm*^+/+^:*INV* (A70.3INV3) and *Atm*^−/−^:*INV* (*Atm*^−/−^INV14) lines ([@bib9]). The pMX-INV retroviral recombination substrate contains GFP cDNA and human CD4 cDNA downstream of an internal ribosomal entry site. For Cre deletion in *Atm*^Tg^*Atm*^flox/−^ abl cells, cells were transfected with mouse stem cell virus--thy1.1-Cre plasmid DNA using the a transfection system (1,500 V/15 ms/4 pulses; Neon; Invitrogen). 24 h after transfection, cells were sorted using biotin anti-Thy1.1 antibodies (BD) and antibiotin microbeads according to the company's protocol (Miltenyi Biotec). The sorted cells were subcloned by limiting dilution and identified using a 3′ ATM southern probe from a 635-bp fragment generated by PCR using 5′-GGCATCTGCT­TGACTGCAGTA­AATCAGGCGG-3′ and 5′-GGGGTACTGCAGCATAGGGCTGGAAGAGG-3′ primers with standard procedures as described previously ([@bib77]).

Western blotting
----------------

Whole-cell lysates from single-cell suspensions of thymocytes or B lymphocytes were prepared as previously described ([@bib24]), and Western blotting was performed as previously described ([@bib20]). In brief, 40 µg protein was loaded on 4--12% Bis-Tris gels (NuPAGE; Life Technologies) and probed with the following antibodies using HRP-conjugated secondary antibodies and ECL Western blotting detection reagents (GE Healthcare): ATM (clone 5C2; 1:400; Novus Biologicals), α-Tubulin (clone B512; 1:30,000; Sigma-Aldrich), KAP1 S824p (1:700; Bethyl Laboratories, Inc.), CHK1 S317p (1:500, Bethyl Laboratories, Inc.), and SMC1 (1:8,000; Novus Biologicals). Human ATM complexes were purified from 293T cells by sequential anti-Flag and anti-HA immunoprecipitation, and kinase assays were performed as previously described ([@bib41]). In brief, kinase assays were performed in kinase buffer composed of 50 mM Hepes, pH 7.5, 50 mM KCl, 5 mM MgCl~2~, 10% glycerol, 1 mM ATP, and 1 mM DTT for 90 min at 30°C.

Online supplemental material
----------------------------

Fig. S1 shows that integration of the *Atm* D2899A mutant transgene in each founder occurs on a different chromosome than endogenous *Atm* using metaphase FISH. Fig. S2 shows that ATM kinase activity is dispensable for ATM recruitment to DNA breaks using laser microirradiation and immunofluorescence microscopy. Fig. S3 shows FACS histograms of YFP expression in bone marrow and spleen subsets and Southern blot analysis of digested genomic DNA assaying for rearrangement of the pMX-INV--integrated substrate within v-Abl--transformed pre-B cell lines, indicative of RAG-dependent DNA recombination. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201204035/DC1>.
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